On December 20, 2023, Nam Ha Pharmaceutical Joint Stock Company successfully organized a conference to review the business operations of 2023 and launch the plans for 2024.

The conference was attended by the Board of Directors, the Supervisory Board, the Management Board, shareholders, partners, and all exemplary leaders of departments and staff.

The Conference on the Review of 2023 Business Operations and Launch of 2024 Plans of NamHa Pharma was successful

At the conference, the CEO of Nam Ha Pharmaceutical Joint Stock Company presented an overview report of the business operations of 2023 with many highlights. Along with the global economic downturn in 2023, the pharmaceutical industry, in particular, faced numerous challenges. However, NamHa Pharma remained resilient, responding promptly to changes, and creating new values to achieve its set goals.

Thanks to the positive results achieved, in 2023, NamHa Pharma remarkably became a Vietnamese National Brand, Top 500 largest enterprises in Vietnam, Top 5 reputable Vietnamese traditional medicine companies, Top 10 innovative and efficient enterprises, and continued to receive certification as High-Quality Vietnamese Products. These achievements reflect the collective strength of the entire team, alongside resolute guidance from the Board of Directors, Supervisory Board, and the creative, flexible, and responsible leadership and unanimous effort of all employees.

The General Director of Nam Ha Pharmaceutical Joint Stock Company is reporting on the business operations of 2023

Recognizing that the market in 2024 continues to pose challenges and aiming for higher growth compared to 2023, the CEO emphasized the continued focus on researching and developing new products, enhancing manufacturing capacity, expanding the market, developing retail customers, boosting domestic sales, and increasing exports to foreign markets.

Also at the conference, the Production Director and branch representatives provided assessments of the advantages, difficulties, and obstacles encountered during operations, proposing measures to implement to leverage the achievements of 2023, address existing issues, and contribute to boosting business operations in 2024, striving to fulfill the tasks assigned by the leadership.

The Production Director stated plans to intensify business operations in 2024

Branch representatives expressed determination to achieve the goals of 2024

Based on the reports presented at the conference, the Chairman of the Board of Directors of Nam Ha Pharmaceutical Joint Stock Company acknowledged and commended the encouraging results achieved by the leadership and employees of NamHa Pharma in 2023. Additionally, while assessing the challenging global and domestic economic situations, the Chairman emphasized the need for the leadership and employees of the company to make concerted and determined efforts to implement more effective and cohesive solutions based on strategic vision and development goals for 2023.

The Board of Directors has high expectations for the Executive Board and the staff of NamHa Pharma in 2024

On behalf of the Board of Directors, the Chairman encouraged all employees of NamHa Pharma to strive harder and ceaselessly endeavor to successfully achieve the set business goals. Additionally, the Board expressed gratitude to the entire team for their tireless efforts and dedication over the past year. The Board of Directors will accompany and provide timely support to overcome obstacles and improve the company’s operational efficiency.

With “Solid Internal Strength – United Efforts for Breakthroughs,” the conference implemented the protocol to launch the business plan for 2024. The leadership and employees of NamHa Pharma are determined to unite, work together, and strive to achieve the goals set for 2024.

The company’s leadership, together with “united efforts,” drives sustainable development for Nam Ha

The conference concluded successfully on the same day!